Peripheral blood parameter abnormalities precede therapy-related myeloid neoplasms after autologous transplantation for lymphoma.
autologous peripheral blood stem cell transplantation
lymphoma
peripheral blood parameters
therapy-related myeloid neoplasms
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
revised:
15
11
2021
received:
02
07
2021
accepted:
18
11
2021
pubmed:
29
12
2021
medline:
7
4
2022
entrez:
28
12
2021
Statut:
ppublish
Résumé
Therapy-related myeloid neoplasms (t-MN) are a leading cause of nonrelapse mortality after autologous peripheral blood stem cell transplantation (aPBSCT) in patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphomas (NHL). t-MN patients treated at an earlier stage of disease evolution have a better prognosis, and this presents a need to identify patients at risk for t-MN. Using a prospective longitudinal study design, this study evaluated peripheral blood parameters pre-aPBSCT and on day 100, at 6 months, 1 year, 2 years, and 3 years in 304 patients treated with aPBSCT. The relation between peripheral blood parameters and subsequent development of t-MN was examined, and nomograms were developed to identify patients at risk for t-MN. Twenty-one patients developed t-MN at a median of 1.95 years post-aPBSCT. Hemoglobin, hematocrit, white blood cell, and platelet counts were lower among patients who developed t-MN compared to those who did not; these differences appeared soon after aPBSCT, persisted, and preceded development of t-MN. Older age at aPBSCT (hazard ratio [HR] Abnormalities in peripheral blood parameters can identify patients at high risk for t-MN after aPBSCT for HL or NHL, allowing opportunities to personalize close surveillance and possible disease-modifying interventions.
Sections du résumé
BACKGROUND
Therapy-related myeloid neoplasms (t-MN) are a leading cause of nonrelapse mortality after autologous peripheral blood stem cell transplantation (aPBSCT) in patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphomas (NHL). t-MN patients treated at an earlier stage of disease evolution have a better prognosis, and this presents a need to identify patients at risk for t-MN.
METHODS
Using a prospective longitudinal study design, this study evaluated peripheral blood parameters pre-aPBSCT and on day 100, at 6 months, 1 year, 2 years, and 3 years in 304 patients treated with aPBSCT. The relation between peripheral blood parameters and subsequent development of t-MN was examined, and nomograms were developed to identify patients at risk for t-MN.
RESULTS
Twenty-one patients developed t-MN at a median of 1.95 years post-aPBSCT. Hemoglobin, hematocrit, white blood cell, and platelet counts were lower among patients who developed t-MN compared to those who did not; these differences appeared soon after aPBSCT, persisted, and preceded development of t-MN. Older age at aPBSCT (hazard ratio [HR]
CONCLUSIONS
Abnormalities in peripheral blood parameters can identify patients at high risk for t-MN after aPBSCT for HL or NHL, allowing opportunities to personalize close surveillance and possible disease-modifying interventions.
Identifiants
pubmed: 34962652
doi: 10.1002/cncr.34072
pmc: PMC8917051
mid: NIHMS1762599
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1392-1401Subventions
Organisme : NCI NIH HHS
ID : P50 CA107399
Pays : United States
Organisme : Leukemia and Lymphoma Society
ID : 2192
Informations de copyright
© 2021 American Cancer Society.
Références
Blood. 1998 Jun 15;91(12):4496-503
pubmed: 9616144
Haematologica. 1999 Dec;84(12):1085-7
pubmed: 10586209
J Clin Oncol. 2000 Mar;18(5):963-71
pubmed: 10694545
Bone Marrow Transplant. 2003 Aug;32(3):317-24
pubmed: 12858205
Blood. 2000 Mar 1;95(5):1588-93
pubmed: 10688812
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Blood. 2005 Jun 1;105(11):4215-22
pubmed: 15701723
Blood. 2003 Mar 1;101(5):2015-23
pubmed: 12393427
J Clin Oncol. 2017 May 10;35(14):1598-1605
pubmed: 28068180
J Clin Oncol. 2000 Mar;18(5):947-55
pubmed: 10694543
Curr Hematol Malig Rep. 2019 Dec;14(6):536-542
pubmed: 31696381
Nature. 2015 Feb 26;518(7540):552-555
pubmed: 25487151
J Clin Oncol. 2006 Aug 1;24(22):3604-10
pubmed: 16877727
J Clin Oncol. 2005 Sep 20;23(27):6699-711
pubmed: 16170178
Leuk Res. 2012 Jan;36(1):1-5
pubmed: 21920601
J Clin Oncol. 2008 Mar 10;26(8):1364-70
pubmed: 18323559
Blood. 1997 Apr 1;89(7):2578-85
pubmed: 9116305
J Clin Oncol. 1999 Oct;17(10):3128-35
pubmed: 10506609
Br J Haematol. 1996 Nov;95(2):349-53
pubmed: 8904891
Am J Hematol. 2015 May;90(5):E80-5
pubmed: 25653205